Published : 12 May 2015

---

Aagami has successfully delivered yet another assignment.

Licensing agreement done for Client’s Novel Antibiotic Product Drug for Canada. Client Partner will register the product and sell exclusively in Canada. Aagami looks forward to repeating the success for US region as well.

Client’s asset is a Novel Antibiotic Product to combat antimicrobial resistance. It is designed specifically to target growing bacterial resistance mechanisms. Client’s partner in Canada is a privately-held pharmaceutical company with a focus on meeting the needs of patients, physicians and partners, and are located in Ontario, Canada.

Aagami wishes best of continued success to both parties and is excited to realise more possibilities, together.